Debate: Hodgkin lymphoma patient who remains PET+ at the end of chemotherapy - SCT-based therapy

Debate: Hodgkin lymphoma patient who relapses after autologous SCT - Allogeneic SCTПодробнее

Debate: Hodgkin lymphoma patient who relapses after autologous SCT - Serial novel agentsПодробнее

Debate: Best Second-line Approach to Induce Lymphoma Remission Prior to SCT? - BrentuximabПодробнее

Debate: A Case of Stage I Follicular Lymphoma - Radiation +/- systemic treatmentПодробнее

Hodgkin disease: The past, the present, and the futureПодробнее

Debate in Hodgkin lymphoma (CO.LYMPH 10/2022)Подробнее

Debate: Best pre-transplant second line therapy for relapsed Hodgkin lymphoma - Chemo aloneПодробнее

Debate: Hodgkin lymphoma patient who remains PET+ at the end of chemotherapy - Radiation therapyПодробнее

Debate: Best second line therapy for relapsed Hodgkin lymphoma - Brentuximab alone/+ chemoПодробнее

Dr Graham Collins, Hodgkin Lymphoma - A Difficult Relapse at the BSH ASM, Glasgow 2016Подробнее

Radiation in Hodgkin Lymphoma - Who should get it, who should not get it?Подробнее

Hodgkin’s Lymphoma Treatment Adapted after Interim PET-CTПодробнее

Debate: Brentuximab vedotin as upfront therapy for advanced Hodgkin lymphoma? - YesПодробнее

Debate: Best Second-line Approach to Induce Lymphoma Remission Prior to SCT? - ChemotherapyПодробнее

How I Manage Advanced Stage Hodgkin Lymphoma and What Do I Do at First RelapseПодробнее

Debate: Recurrent Hodgkin's lymphoma after ASCT in CR on brentuximab vedotin - AllotransplantПодробнее

How can we make Hodgkin's disease therapy less toxic and more effective?Подробнее

Debate: Is watch and wait dead in follicular lymphoma? - YesПодробнее

Ann LaCasce: PET Adapted Therapy Allows Omission of Radiation Therapy in Classic Hodgkin LymphomaПодробнее